U.S.S.N. 09/731,632 Case No. 18906IAR Page No. 2

This listing of claims will replace all prior versions and listings of claims in the application:

## **Listing of Claims:**

and

Claim 1. (Currently amended) An assay for determining the cyclooxygenase- 2 activity of a sample of a composition comprising a human osteosarcoma cell preparation, a sample and arachidonic acid, the assay comprising the steps of:

- (a) preparing the composition by adding
  - (1) a-the human osteosarcoma cell preparation,
- (2) a the sample, said sample comprising a putative cyclooxygenase-2 inhibitor,

Claim 2. (Currently amended) An assay for determining the cyclooxygenase 2

- (3) the arachidonic acid; and
- (b) determining the amount of prostaglandin E<sub>2</sub> produced in step (a).

activity of a sample according to claim 1 comprising the steps of:

(a) adding

(1) a human osteosarcoma cell preparation,

(2) a sample, said sample comprising a putative cyclooxygenase 2 inhibitor, and

(3) arachidonic acid; and

(b) determining the amount of prostaglandin E<sub>2</sub> produced in step (a),

wherein the cell preparation comprises  $10^3$  to  $10^9$  whole cells of osteosarcoma per cc, or 50 to 500 ug of osteosarcoma microsomes per ml of preparation; and 0.1 to 50  $\mu$ l of arachidonic acid per ml of preparation.

Claim 3. (Currently amended) An assay for determining the cyclooxygenase-2 activity of a sample a composition comprising a human osteosarcoma cell preparation, a sample and arachidonic acid, the assay comprising the steps of:

- (a) preparing the composition by adding
  - (1) a the human osteosarcoma cell preparation,
- (2) a <u>the</u> sample, said sample comprising a putative cyclooxygenase-2 inhibitor, and
  - (3) the arachidonic acid; and
  - (b) determining the amount of prostaglandin E<sub>2</sub> produced in step (a)
- (c) correlating the amount of prostaglandin E<sub>2</sub> produced with cyclooxygenase-2 activity, wherein the osteosarcoma cell preparation consists essentially of osteosarcoma 143.98.2 microsomes.

Claim 4. (Original) An assay according to claim 3 wherein the osteosarcoma 143.98. 2 microsomes are substantially free of endogenous arachidonic acid.

Claim 5. (Original) An assay according to claim 3 wherein the microsomes are contacted with an amount of delipidized serum protein effective to reduce the amount of endogenous arachidonic acid in the microsomes by a factor of at least approximately 2.

Claim 6. (Currently amended) An assay for determining the cyclooxygenase-2 activity of a sample a composition comprising a human osteosarcoma cell preparation, a sample and arachidonic acid, the assay comprising the steps of:

- (a) preparing the composition by adding
  - (1) a the human osteosarcoma cell preparation,

- (2)  $\frac{1}{2}$  the sample, said sample comprising a putative cyclooxygenase-2 inhibitor, and
  - (3) the arachidonic acid; and
  - (b) determining the amount of prostaglandin E2 produced in step (a),
- (c) correlating the amount of prostaglandin E<sub>2</sub> produced with cyclooxygenase-2 activity, wherein the human osteosarcoma cell preparation contains no recombinant vector.

Claim 7. (Currently amended) An assay for determining the cyclooxygenase-2 activity of a sample a composition comprising a human osteosarcoma cell preparation, a sample and arachidonic acid, the assay comprising the steps of:

- (a) preparing the composition by adding
  - (1) a the human osteosarcoma cell preparation,
- (2) a the sample, said sample comprising a putative cyclooxygenase-2 inhibitor, and
  - (3) the arachidonic acid; and
  - (b) determining the amount of prostaglandin E2 produced in step (a)
- (c) correlating the amount of prostaglandin E<sub>2</sub> produced with cyclooxygenase-2 activity, wherein the osteosarcoma cell preparation consists essentially of whole cells of osteosarcoma 143.98.2.

Claim 8. (Canceled).

Claim 9. (Previously amended) A composition comprising:

U.S.S.N. 09/731,632 Case No. 18906IAR Page No. 5

- (a) an osteosarcoma cell preparation having  $8x10^4$  to  $2x10^6$  osteosarcoma 143.98.2 whole cells per cc of cell preparation or 100 to 400  $\mu g$  of osteosarcoma 143.98.2 microsomes; and 10 to 20  $\mu l$  of peroxide-free arachidonic acid per cc of cell preparation; and
  - (b) 0.1 to 50 µl of arachidonic acid per cc of cell preparation.

Claim 10. (Original) A composition according to claim 9 wherein the microsomes are substantially free of endogenous arachidonic acid.


Claim 11. (Currently amended) An assay for determining the cyclooxygenase-1 activity of a sample a composition comprising the steps of:

- (a) preparing the composition adding
  - (1) a the COX-1 cell preparation,
  - (2) a the sample, said sample comprising a putative cyclooxygenase-1 inhibitor;
  - (3) the arachidonic acid; and
- (b) determining the amount of prostaglandin E2 produced in step (a)
- (c) correlating the amount of prostaglandin E2 produced with cyclooxygenase-2 activity.

Claim 12. (Original) An assay according to claim 11 wherein the COX-1 cell preparation consists essentially of whole cells of U-937.

Claim 13. (Original) An assay according to claim 11 wherein the COX-1 cell preparation consists essentially of U-937 microsomes.

Claim 14. (Currently amended) An assay according to claim 11 for determining the cyclooxygenase 1 activity of a sample comprising the steps of:



(2) a sample, said sample comprising a putative cyclooxygenase-1 inhibitor;

(3) arachidonic acid; and

(b) determining the amount of prostaglandin E<sub>2</sub> produced in step (a),

wherein the cell preparation comprises 10<sup>5</sup> to 10<sup>8</sup> whole cells of U-937 per cc, or 1 to 10 mg of U-937 microsomes per ml of preparation; and

Claim 15. (Original) An assay according to claim 14 wherein the cell preparation comprises  $8x10^8$  to  $1.5x10^6$  whole cells of U-937 per cc, or 1 to 5 mg of U-937 microsomes per ml of preparation.

Claims 16 to 18 (Canceled)

0.1 to 50 µl of arachidonic acid per ml of preparation.

Claim 19. (Currently amended) A transformed host cell that expresses cyclooxygenase-2 as shown in SEQ. ID. NO: 10 comprising:

- (a) a mammalian or eukaryotic expression vector; and
- (b) a sequence encoding human cyclooxygenase-2 comprising bases 97 to 1909 of as shown in FIG. 2 (SEQ. ID. NO: 11) or encodes protein of FIG. 1 (SEQ. ID. NO: 10).

Claims 20 to 21 (Canceled).

Claim 22. (Previously amended) Human cyclooxygenase-2 cDNA comprising the coding region which is bases 97 to 1909 of SEQ. ID. NO: 11.

Claim 23. (Previously amended) Recombinant human cyclooxygenase-2 which is shown in SEQ. ID. NO: 10.

Claim 24. (Previously amended) An isolated human cyclooxygenase-2 which is shown in SEQ. ID. NO: 10.

U.S.S.N. 09/731,632 Case No. 18906IAR Page No. 7

Claim 25. (Previously amended) Purified human cyclooxygenase-2 which is shown in SEQ. ID. NO: 10.

Claim 26. (Previously amended) The transformed host cell according to claim 19 wherein the expression vector is a vacinia or baculovirus vector.

Claim 27. (Previously amended) The transformed host cell according to claim 19 wherein the cyclooxygenase-2 is expressed in COS-7 cells.